Organ Preservation in Focus: Terumo’s $1.5B Acquisition of OrganOx

Organ transplantation has transformed modern medicine, yet one of the greatest hurdles remains the preservation of donor organs between recovery and implantation. Organ preservation refers to the methods and technologies used to keep hearts, livers, kidneys, lungs, and other organs viable until they can be transplanted into recipients. The effectiveness of preservation directly influences patient outcomes, organ utilization rates, and the economics of transplant programs.

For decades, static cold storage (SCS) has been the gold standard. Organs are cooled on ice to slow metabolism, a simple and inexpensive solution that works reasonably well at scale. But it has major shortcomings: cold storage cannot prevent ischemic injury, it provides no way to test organ function before transplant, and it contributes to the high rate of discarded organs.

This is where OrganOx has made its mark. The company’s metra system, an NMP platform for livers, allows surgeons to keep donor livers “alive” outside the body, improving utilization and decision-making before transplantation.

Terumo’s Acquisition of OrganOX

In August 2025, Terumo Medical Corporation announced its $1.5 billion acquisition of OrganOx, following a prior venture investment in March. The transaction is one of the largest medtech M&A deals of the year, raising the annual deal count to 31.

For Terumo, a Japanese multinational with deep expertise in cardiopulmonary and perfusion technologies, the move is a natural extension. It reflects a broader trend of global strategics targeting high-value therapeutic areas where patient need and commercial opportunity align. At the heart of this acquisition is the recognition that improving organ preservation could unlock thousands of additional transplants each year.

For more information visit here: https://www.lifesciencemarketresearch.com/insights/organ-preservation-in-focus-terumos-15b-acquisition-of-organox

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more